EndoPredict is a 2nd generation multi-gene breast cancer recurrence test for pre- or postmenopausal women newly diagnosed with early-stage breast cancer.
Created for the purpose of highly accurate assessment of 5 to year risk of distant recurrence of the disease EndoPredict combines into an unique indicator EPClin score gene expression with clinically pathological features providing outstanding prognostic performance that will ensure the healthcare professional cancer hormonal therapies chemotherapy is or is not required to accompany endocrine treatment.
Considering these aspects, realizing that the cancer has a cancer hormonal therapies or low risk of recurrence can help patients and doctors decide if chemotherapy after surgery is or is not necessary to accompany endocrine therapy.
Cancer hormonal therapies
What DNA sample is required to perform the test? EndoPredict requires a simple tumor tissue sample that is customarily prepared for the pathology exam upon surgical tumor removal.
The latest diagnostic and prognostic technology allows healthcare specialists to determine suitable treatment procedures based completely on the needs and DNA of the patient. What is MGD? Therefore, the decision of breast cancer therapy increasingly depends on your own mix of gene markers.
Cancer hormonal therapies. Cancer hormonal therapy
In this context, EndoPredict reveals critical information about the way that a tumor is likely to react at a genetic level. Why is EndoPredict relevant?
At the same time it can convince those at low risk of recurrence that chemotherapy is not mandatory. Thus, the test is practically an important step ahead towards the goal of truly customized care, helping breast cancer therapists to avoid both over- and under treatment of breast cancer with chemotherapy.
Cancer hormonal therapy
When do breast cancer metastases occur? Breast cancer metastases mostly happen within the first three years following the initial diagnosis.
One of papanicolaou anormal objectives of EndoPredict test is to calculate the tendency for cancer recurrence or late metastases. What is the best treatment to lower the risk of developing a recurrence of the breast cancer?
For early and locally advanced breast cancer the first clinical step is, of course, to surgically remove the tumor. Gastric cancer young adults Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? Around half of the intermediate patients currently receive unnecessary chemotherapy, which is very stressful for the organism, has serious side-effects, cancer hormonal therapies toxic by nature and has a significant impact on mortality.
For that reason, it is very important to cancer hormonal therapies able to identify the patients who would not cancer hormonal therapies benefit from chemotherapy in any case and to be able to provide a more focused care, including systemic endocrine therapy, instead.
EndoPredict manages to make this happen. The result?
Primary Outcome Measures: 1.